Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · IEX Real-Time Price · USD

1.140

-0.010 (-0.87%)

At close: Jul 2, 2024, 4:00 PM

1.190

+0.050 (4.39%)

After-hours: Jul 2, 2024, 7:52 PM EDT

Aclaris Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Net Income	-88.48	-86.91	-90.87	-51.02	-161.35	Upgrade
Depreciation & Amortization	0.86	0.8	0.92	1.32	6.41	Upgrade
Share-Based Compensation	20.54	15.04	14.06	11.21	16.18	Upgrade
Other Operating Activities	-11.25	3.51	23.75	-0.15	42.32	Upgrade
Operating Cash Flow	-78.33	-67.57	-52.13	-38.63	-96.45	Upgrade
Capital Expenditures	-1.31	-0.61	-0.31	-0.45	-1.61	Upgrade
Acquisitions	0	0	0	0	34.19	Upgrade
Change in Investments	47.53	13.23	-167.32	6.84	73.11	Upgrade
Investing Cash Flow	46.22	12.63	-167.63	6.39	105.68	Upgrade
Share Issuance / Repurchase	26.81	72.9	239.66	7.81	0.21	Upgrade
Debt Issued / Paid	0	0	-11.48	10.78	-30.52	Upgrade
Other Financing Activities	-0.1	-0.03	-3.12	-0.21	-	Upgrade
Financing Cash Flow	26.71	72.87	225.05	18.37	-30.32	Upgrade
Net Cash Flow	-5.4	17.93	5.29	-13.87	-21.08	Upgrade
Free Cash Flow	-79.63	-68.17	-52.44	-39.09	-98.06	Upgrade
Free Cash Flow Margin	-254.84%	-229.13%	-775.65%	-602.99%	-2319.80%	Upgrade
Free Cash Flow Per Share	-1.14	-1.04	-0.92	-0.92	-2.37	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).